The fair value estimate for Advanced Enzyme Technologies is held at ₹370, with analysts choosing not to shift their valuation anchor despite refreshed model inputs. That steady price target lines up with commentary that the key question now is execution against the current plan rather than a change in the core story. As you read on, you will see how this stable ₹370 figure fits into the evolving analyst narrative and what it means for your own view on the stock. Stay updated as the Fair Value...